Puretech Health

Puretech Health's phase IIb data shows its deuterium-modified pirfenidone improves tolerability and efficacy in treating idiopathic pulmonary fibrosis.

PureTech's Phase IIb trial of deupirfenidone met endpoints, slowing lung degeneration in IPF patients. The trial evaluated 550mg and 825mg doses over 26 days, with the high dose showing superior efficacy in slowing lung function decline compared to placebo. The company aims to establish deupirfenidone as a new standard of care for IPF.

PureTech's deupirfenidone (LYT-100) in ELEVATE IPF Phase 2b trial achieved primary and key secondary endpoints, showing 98.5% probability of superiority over placebo in slowing lung function decline. The 825 mg TID dose demonstrated an 80.9% treatment effect vs placebo (-21.5 mL vs. -112.5 mL decline), significantly outperforming pirfenidone's 54.1% effect (-51.6 mL vs. -112.5 mL). Both doses showed favorable tolerability, with over 90% of trial completers enrolling in the ongoing open-label extension study.

© 2024 www.detroitnews.com

AI has contributed to drug development, including the creation of a new schizophrenia medication, Cobenfy, through AI-powered predictive algorithms. This innovation highlights the potential for greater AI healthcare advancements in the coming decade.

Insilico Medicine plans to advance ISM001-055 into a pivotal study after positive Phase IIa trial results showing efficacy against idiopathic pulmonary fibrosis (IPF). ISM001-055 improved forced vital capacity (FVC) and was safe and well-tolerated. Insilico aims to initiate a global Phase IIb study by the second half of 2025, with Carol Satler, MD, PhD, appointed to oversee the program. The drug targets Traf2- and NCK- interacting kinase (TNIK) and was developed using generative AI.

Trump's presidency may bring changes to federal health agencies, with potential influence from Robert F. Kennedy Jr. on FDA policies. The drug industry is concerned about Kennedy's role, while biotech leaders are optimistic about reduced scrutiny of mergers and acquisitions under the FTC. Trump's potential policies on drug pricing and U.S. firms' ties to China are also under scrutiny.

Punjab Transport Minister Laljit Singh Bhullar directs officials to fast-track regularization of government bus drivers and conductors, aiming for Cabinet approval. Key policy shifts include transitioning outsourced workers to permanent positions, implementing a 5% annual salary increase, and increasing night stay allowances. Bhullar also announces a structured pathway for outsourced employees to secure regular government positions, addressing long-standing demands.

Insilico Medicine appoints Carol Satler, M.D., PhD, as VP for Non-oncology Clinical Development, to lead validation of ISM001-055 for idiopathic pulmonary fibrosis and strategic planning for non-oncology assets. Satler, with 20+ years of experience at Pfizer, Sanofi, Bayer, Takeda/Millennium, Puretech Health, and Gilead, aims to accelerate clinical validation and bring transformative therapies to market using AI.